

Education Day

Thursday, November 17, 2011

7:00-9:00 am Breakfast in the Foyer

Stereotactic Radiosurgery and Radiation Biology in the CNS

Grand Ballroom A-D

8:10-8:20 am Welcome – Education Day
Introduction
Co-Chairs: Eric Chang, Arjun Sahgal, Jason Sheehan

Morning Session: Radiosurgery and Stereotactic Body Radiation Therapy for the CNS

8:20-8:40 am Introduction to Technology of Radiosurgery and Stereotactic Body Radiation Therapy: Evolution from Brain to Spine
Arjun Sahgal

8:40-9:00 am Introduction to Spine Stereotactic Body Radiation Therapy: What is it? What are the outcomes? What are the issues, controversies?
Arjun Sahgal

9:00-9:20 am Radiosurgical decompression of spinal cord compression
Sam Ryu

9:20-9:40 am Surgery for malignant epidural spinal cord compression
Ziya Gokaslan

9:40-10:00 am Normal tissue tolerance and spinal radiosurgery: Lessons from preclinical studies
Paul Medin

10:00-10:20 am *Break*

10:20-10:40 am Stereotactic body radiation therapy and minimally invasive surgery for spine: a new paradigm
Peter Gerszten

10:40-11:00 am Skull Base Radiosurgery: Current knowledge and unanswered questions
Jason Sheehan

11:00-11:20 am Radiation therapy for brain metastases based on the currently available evidence
Eric Chang

11:20 -11:40 am Radiosurgery for gliomas
Michael Vogelbaum

11:40 -12:00 pm Radiosurgery for the postoperative resection cavity
Paul Brown

12:00 - 1:00 pm *Boxed lunches*

Afternoon Session: Radiation, Biology, and the CNS

1:00-1:30 pm Improving radiation therapy in the brain using DNA repair inhibitors
Thomas Helleday

1:30-2:00 pm Nanodevices and radiation therapy, ways around the barrier?
Mohamed Khan

2:00-2:30 pm MRgFUS induced blood brain barrier disruption and novel drug delivery for brain tumors
Nathan McDannold

2:30-3:00 pm Radiation-induced non-target response: Mechanism and clinical implication
Tom Hei

3:00-3:15 pm *Break*

3:15-3:45 pm Ultrasound, high- and low-dose radiation and apoptosis
Greg Czarnota

3:45-4:15 pm Radiobiology of radiosurgery, response modifiers, and radionecrosis
Sam Chao

4:15-4:45 pm Mechanisms of radiation associated secondary malignancies
Jean Nakamura

SNO thanks Eisai, Inc., for their support of the 2011 Education Day

Concurrent Education Day Session
Quality of Life/Symptom Management
Grand Ballroom E-G

8:00-8:10 am Welcome – Education Day
Mary Lovely

Neuropsychiatric Interventions

8:10-9:10 am Differential Diagnosis of Cognitive and Behavioral Problems
Manmeet Ahluwalia and Michael Glantz

9:10-9:30am Mood and Anxiety Disorders in Patients with Brain Tumors
Brian Appleby

9:30-9:50 am Seizures and Pseudoseizures
Robert Cavaliere

9:50-10:00 am *Break*

Quality of Life Interventions

10:00-10:20 am Driving and other Safety Issues
Mark Shaffrey

10:20-10:40 am Management of Memory and Attention Deficits
Jennie Rexer

10:40-11:00 am Management of Fatigue and Sleep Disorders
Terri Armstrong

11:00-11:20 am Caregiver Burden and Caregiver Interventions
Martin Klein

11:20-11:40 am Management of Disinhibition and Dysexecutive Syndrome
Caroline Racine

11:40-12:00 pm Delirium
Susan B. Turkel

12:00 - 1:00 pm *Boxed lunch*

Quality of Life and SNO

1:00-1:20 pm Needs of SNO Membership Regarding QOL: Results of a SNO Survey
Alixis VanHorn

1:20-1:40 pm General Discussion: Quality of Life Programs

Concurrent Education Day Afternoon Session
Clinical Trials Course for Young Investigators
Grand Ballroom E-G

1:45-2:00 pm Introduction, Overview, Historical Perspective
Susan Chang

2:00-2:20 pm Phase 0 and I Trials: How they can expedite the clinical research agenda
Howard Colman

2:20-2:40 pm Challenges in Phase II Trial Design
Eva Galanis

2:40-3:00 pm Overview of the Basics of Phase III Trials
Mark Gilbert

3:00-3:15 pm *Break*

3:15-3:35 pm Challenges of Response Assessment/Endpoint Evaluations for Surgically Based Studies
Michael Vogelbaum

3:35-3:55 pm Responsibilities of a PI
Manish K. Aghi

3:55-4:20 pm Overview of Regulatory Requirements (Institutional and FDA)
James Markert

4:20-4:45 pm Personal experience in conducting a Clinical Trial: Pearls and Pitfalls
E. Antonio Chiocca

4:45-4:50 pm Summary, Additional Educational Resources
Mark Linskey

Industry Sponsored Satellite Symposia

(Not sponsored by The University of Texas MD Anderson Cancer Center)

5:00-7:15 pm Glioblastoma Multiforme: Applying Best Practices to Clinical Cases
Supported by Genentech
Grand Ballroom A-D

5:00-7:15 pm Selection to Optimize Outcomes for Skull Base Tumor Patients
Supported by Stryker
Terrace Rooms A-F

Welcome Reception

7:30-10:00 pm Welcome Reception
Supported by Genentech
Pool patio

16th Annual Scientific Meeting of the Society for Neuro-Oncology

Friday, November 18, 2011

7:00-9:00 am Breakfast in the Foyer

Sunrise Sessions 7:00-8:00 am

Viral Gene Therapy *Salon VII-VIII*

- Viral Gene Therapy
Juan Fueyo
- Convection-enhanced delivery of oncolytic adenovirus in gliomas
Clemens Dirven
- Pre-clinical development and clinical testing of oncolytic measles virus
Evanthia Galanis
- Retroviral replicating vectors for cancer gene therapy
Noriyuki Kasahara

Surgery for Non-malignant Skull Base Tumors *Terrace A-C*

- Endoscopic versus open approaches to the anterior skull base: A Balanced Dialogue
Ted Schwartz
- Open skull base approaches
Jacques Morcos

Cancer Cell Metabolism *Harbor Room*

- Targeting altered cellular metabolism in EGFR/PI3K-activated glioblastomas
Paul Mischel
- The mitochondria and tumor cell growth
Ralph Deberardinis
- Determining how fat fuels growth in glioma
Steven Bensinger

Advances in Anatomic, Metabolic and Physiologic

Neuroimaging *Pacific Room*

- Genomic correlates of imaging biomarkers
Whitney Pope
- Multiparametric physiological imaging in glioblastoma
Ben Ellingson
- Perfusion MRI in glioma
Kathleen Schmainda
- Non-FDG PET for Glioma
Jeorg Tonn

Plenary Session 8:15-noon

Grand Ballroom

8:15 am Welcome & Meeting Introduction
Co-Chairs: Timothy Cloughesy and Michael Vogelbaum

Top Abstracts 1

Moderated by William Weiss and E. Antonio Chiocca

- 8:30 am MP-07 Metabolic modulation of GBMs by depleting Hexokinase II: potentiating the effect of standard therapies
Alenoush Vartanian
- 8:45 am MP-09 Targeting EGFR/PI3K/Akt regulated SREBP-1/LDLR mediated cholesterol metabolism to treat GBM
Deliang Guo

- 9:00 am CB-01 PTEN phosphorylation by fibroblast growth factor receptors and SRC mediates resistance to epidermal growth factor receptor inhibitors in glioma
Frank Furnari
- 9:15 am NO-15 Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors
Andrew B. Lassman
- 9:30 am ST-22 Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery
Pablo A. Valdes
- 9:45 am OM-05 A CpG Island hypermethylated phenotype (CIMP) in anaplastic oligodendroglial brain tumors is a better predictor of survival than MGMT methylation. A report of EORTC study 26951
Martin J. van den Bent

10:00 am *Break*

- 10:15 am NO-46 RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM)
Mark R. Gilbert
- 10:30 am OM-30 A combined molecular clinical predictor of survival validated with the RTOG-0525 cohort
Erik P. Sulman
- 10:45 am OM-35 Clinical utility of G-CIMP and IDH1 status as dual prognostic markers in glioblastoma
Kenneth D. Aldape
- 11:00 am **President's address and introduction to the Victor Levin Lecture**
Frederick F. Lang
- 11:30 am **Victor Levin Award Lecture**
Biomarker-based approaches to classify brain tumors
Kenneth D. Aldape

12:00- 1:00 pm *Boxed Lunch*

- Young Investigators Roundtables *Pacific Room*
Supported by Genentech
- International Outreach (members welcome) *Harbor Room*
- Industry Supported Event: Current state of the art: Vaccine development in the treatment of GBM
Terrace Room (Not sponsored by The University of Texas MD Anderson Cancer Center)

Concurrent Sessions 1:00-3:00 pm**Cell Biology and Micro-Environment****Grand Ballroom A-D***Moderated by Peter Forsyth and Candace Gladson*

- 1:00 pm RB-05 Understanding radiation injury and neurogenesis using a novel astrocyte-specific inducible mouse model
Robert Bachoo
- 1:15 pm CB-42 Tumor associated mesenchymal stromal cells increase proliferation and maintain stemness of glioma stem cells through the IL6/STAT3 pathway
Anwar Hossain
- 1:30 pm SC-11 Controlling the migration of GBM cells: lessons from neurogenic niches
Linda Chen
- 1:45 pm CB-18 SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans
Shi-Yuan Cheng
- 2:00 pm CB-52 Molecular determinants of dichotomy between proliferation and invasion of glioma cells
Harshil Dhruv
- 2:15 pm CB-70 Asymmetry-defective oligodendrocyte progenitors are glioma precursors
Claudia Petritsch
- 2:30 pm CB-21 Targeted disruption of Stat3 signaling inhibits tumor growth and brain metastases by Caveolin-1 upregulation
Suyun Huang
- 2:45 pm CB-33 Decrypting Chromosome 10q Deletion in Glioblastoma. An Interspecies Comparison of Gene Copy Number Alterations
Adam M. Sonabend

Immunology/Immunotherapeutics**Grand Ballroom E-G***Moderated by Alan Waziri and Linda Liau*

- 1:00 pm IM-03 Long-term follow-up of ACT III: A Phase II trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma
Rose K. Lai
- 1:15 pm IM-12 An in vivo immunotherapy screen identifies Fc-mOX40L as a potent drug capable of causing regression of large murine gliomas
Katherine A. Murphy
- 1:30 pm IM-15 Phase 2 study of gene mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma
E. A. Chiocca
- 1:45 pm IR-03 Intense human cytomegalovirus (HCMV) immune response in

glioblastoma patients: A prognostic factor for survival

Adelaida Garcia-Velasco

- 2:00 pm IM-16 Combining Anti-PD-1 (B7-H1) immunotherapy with stereotactic radiosurgery in a mouse orthotopic glioblastoma model
Jing Zeng

- 2:15 pm IM-25 Radiosurgery for melanoma brain metastases in the Ipilimumab era: Longer survival is possible
Jonathan P. Knisely

- 2:30 pm IR-05 Interleukin-4 receptor α -chain promotes the immunosuppressive activity of glioma-infiltrating monocytes
Gary Kohanbash

- 2:45 pm IM-18 Dendritic cell vaccine therapy for patients with recurrent glioblastoma: A single-institution pooled analysis of four trials
Jethro Hu

3:00 pm *Break***Concurrent Sessions 3:15-5:00 pm****Preclinical****Grand Ballroom A-D***Moderated by Jann Sarkaria and Gelareh Zadeh*

- 3:15 pm AI-24 The role of bone marrow derived cells in tumor stage dependant neo-vascularisation
Kelly Burrell
- 3:30 pm CB-14 Therapeutic potential of AZD1480 for the treatment of human glioblastoma
Braden C. McFarland
- 3:45 pm RB-04 Bone marrow derived progenitors and ionizing radiation in normal brain
Kelly Burrell
- 4:00 pm ET-55 BRaf Inhibitor PLX4720 is a radiosensitizer in human malignant astrocytomas expressing the BRaf V600E mutation
Tina Dasgupta
- 4:15 pm ET-06 Preclinical studies reveal mechanisms of response and adaptation of proneural glioblastoma to Sunitinib
Liang Lei
- 4:30 pm AI-13 Optimization of glioma treatment through suppression of proinvasive RGS4 by mTOR inhibition
Markus Weiler
- 4:45 pm ET-22 Active efflux at the blood brain barrier limits: Effective pharmacotherapy of malignant glioma
John Ohlfest

Radiology

Grand Ballroom E-G

Moderated by Whitney Pope and Sarah Jost

- 3:15 pm ST-40 Confocal Microscopic Fluorescence Imaging of Gliomas
Sameer Sheth
- 3:30 pm RA-16 Diffusion imaging parameters vary with treatment regimen for patients with newly diagnosed glioblastoma multiforme
Laleh Jalilian
- 3:45 pm RA-37 Correlation of MRI imaging characteristics with patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
Whitney B. Pope
- 4:00 pm RA-06 Functional diffusion maps in FLAIR abnormal regions predict survival in both newly diagnosed glioblastoma treated with radiochemotherapy and recurrent glioblastoma treated with bevacizumab
Benjamin M. Ellingson
- 4:15 pm RA-31 Radiogenomic mapping in GBM in patients with high versus low edema/tumor infiltration using an image- genomic analysis of 12, 764 genes and 555 microRNAs
Rivka R. Colen
- 4:30 pm OM-34 Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade glioma
Llewellyn Jalbert
- 4:45 pm NO-52 FET-PET positive brain lesions: A comparison of 18F-FET-PET, MRI and histopathological findings
Martha Nowosielski

Industry Satellite Symposia 5:00-7:15 pm

(Not sponsored by The University of Texas MD Anderson Cancer Center)

- 5:00-7:15 pm Glioblastoma: Expert Perspectives on Current Standards of Care and Novel Approaches
Supported by Merck
Grand Ballroom A-D
- 5:00-7:15 pm Adaptive Hybrid Surgery: Optimizing Outcomes for Benign Skull Base Tumor Patients
Supported by Brainlab
Grand Ballroom E-G

Poster Viewing Reception I 7:30-9:30 pm

Royal Ballroom

Supported by Merck

Saturday, November 19, 2011

7:00-9:00 am

Breakfast in the Foyer

Sunrise Sessions 7:00-8:00 am

Brain Cancer Cells of Origin Salon VII-VIII

- Non-stem cell origin for oligodendroglioma
William Weiss
- Glioblastoma cancer stem-like cells contribute to tumor endothelium
Vivian Tabar
- Conflict of interest: An oppositional relationship between stemness and p53 in malignant glioma
Chuck Stiles

Intraoperative Surgical Adjuncts for Visualizing Tumor

Terrace A-C

- Laser Interstitial Thermal Therapy
Gene Barnett
- 5-ALA
Constantinos Hadjipanayis
- Nanoparticles
Steven Toms

Neurological Complications of Cancer Therapy in the CNS Pacific Room

This session is jointly organized by SNO and the American Academy of Neurology

- Introduction
Lisa Rogers
- Complications of radiotherapy and chemotherapy
Lisa DeAngelis
- Effect of RT and chemotherapy on neural stem stems and cognitive function
Michelle Monje
- Neurologic complications of targeted molecular therapies
Patrick Wen

Diffuse Intrinsic Pontine Gliomas and Other Pediatric Astrocytic Tumors Harbor Room

- Current concepts for low grade and high grade glioma and diffuse brainstem glioma: Issues and challenges
Michael Prados
- Diffuse infiltrating brainstem glioma, current approaches and new strategies
Mark Kieran
- Low grade glioma in children/implications of BRAF alterations
Theodore Nicolaides
- High grade astrocytoma/glioma in children, current approaches and new strategies
Tobey MacDonald

Neuro-Oncology in Korea: A KSNO/SNO Joint Session

Salon I

- Foundation History of the Korean Society for Neuro-Oncology
Seung Hoon Lee

- Plan for Multicenter Clinical Trial for Standardization of Therapeutic Guidelines in Malignant Gliomas in Korea
Yong Kil Hong
- Temozolomide for Brain Tumors: Is There Room for Expansion?
Mark Gilbert
- Practice Guidelines for Gliomas
Mark Linskey

Plenary Session 8:15-12:0 pm

Grand Ballroom

Top Abstracts 2

Moderated by Ingo Mellinghoff and Ian Pollack

- 8:15 am QL-03 Clinical utility of Quality of Life (QOL) and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525
Terri Armstrong
- 8:30 am EP-08 Inherited variants impact survival in uniformly-treated glioblastoma patients
Yuanyuan Xiao
- 8:45 am PC-02 Efficacy of bevacizumab + CPT-11 in children with recurrent low grade glioma (LGG) - a Pediatric Brain Tumor Consortium study
Sridharan Gururangan
- 9:00 am PC-07 Cumulative cisplatin dose does not correlate with event-free and overall survival outcomes in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy
Amulya A. Nageswara Rao
- 9:15 am PL-10 Transposonogenetics implicates a novel RhoGAP and other genetic drivers of primitive neuroectodermal tumors
David A. Largaespada
- 9:30 am PL-14 Identifying genes that promote leptomeningeal dissemination in Sonic Hedgehog-driven murine medulloblastoma
Daniel W. Fults
- 9:45 am **Lifetime Achievement Award**
Jerome Posner

9:55 am Break

- 10:10 am SC-25 Seeing is believing: Utilization of intravital microscopy to evaluate tumor growth and therapeutic

- 10:25 am SC-21 response of transplanted human glioma stem cells
Justin D. Lathia
- 10:40 am IR-01 Glioblastoma stem cell subtypes display different patterns in neural differentiation, growth, and invasiveness
Jun Fu
- 10:55 am ET-42 Cytomegalovirus subverts the monocyte lineage to become glioma propagating
Kristine Dziurzynski
- 11:10 am SC-26 NF1-deficiency defines a subgroup of GBM sensitive to clinically available MEK inhibitors
Wendy See
- 11:25 am Contribution of microglia to radioresistance and mesenchymal differentiation in glioblastoma
Krishna Bhat
- Keynote Lecture**
Introduction: *Timothy Cloughesy*
Using Cancer Genetics to Guide Drug Target Selection: Lessons from Gleevec and Beyond
William G. Kaelin Jr., MD
Professor of Medicine, Harvard Medical School

Noon- 1:00 pm *Boxed Lunch*

- Industry Supported Event: Current state of the art: Vaccine development in the treatment of GBM
Terrace Room (Not sponsored by The University of Texas MD Anderson Cancer Center)
- SNO Business Meeting *Pacific Room*

Concurrent Sessions 1:00-3:00 pm

Grand Ballroom A-D

-omics

Moderated by Cameron Brennan and Howard Colman

- 1:00 pm OM-08 Fine mapping of the germline 8q24 region associated with the development of oligodendroglioma
Robert B. Jenkins
- 1:15 pm OM-23 Aberrant transcriptional activation is associated with gene body hypomethylation in glioblastoma
Raman P. Nagarajan
- 1:30 pm OM-21 C/EBP- β and C/EBP- δ , master regulators of the mesenchymal transition in glioblastoma, are highly correlated with extent of necrosis and strongly expressed by hypoxic pseudopalisading cells
Daniel J. Brat

- 1:45 pm OM-04 Multidimensional integrated molecular profiling of grade II & III diffuse astrocytomas reveal distinct subclasses correlated with clinical outcome
Daniel Gorovets
- 2:00 pm OM-06 miR-181d: a predictive glioblastoma biomarker that down-regulates MGMT expression
Clark Chen
- 2:15 pm OM-16 Gene expression profiling of glioblastomas is more accurate than recursive partitioning analysis and MGMT methylation for predicting temozolomide responsiveness
Robert W. Cook
- 2:30 pm OM-27 The effect of tumor subtype on survival and the graded prognostic assessment (GPA) for patients with breast cancer and brain metastases
Paul W. Sperduto
- 2:45 pm OM-36 Metabolic characterization of glioma populations
Adam Elkhaled

Pediatrics Clinical/Laboratory

Grand Ballroom E-G

Moderated by *Maryam Fouladi*

- 1:00 pm PC-21 Stereotactic brachytherapy with 125Iodine seeds (SBT) for the treatment of inoperable low grade gliomas in children: long-term outcome of 147 patients
Maximilian I. Ruge
- 1:15 pm PC-15 Final report on outcome of children with newly diagnosed high grade glioma (HGG) treated with multi-drug induction chemotherapy followed by consolidative myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue (AuHPCR) on the "Head Start" II and III protocols
Juan Espinoza
- 1:30 pm PC-14 A Phase I study of the combination of vandetanib and dasatinib administered during and after radiotherapy (RT) in children with diffuse intrinsic pontine glioma (DIPG)
Alberto Broniscer
- 1:45 pm CB-20 CXCR4 activation defines a new subgroup of Sonic Hedgehog driven Medulloblastomas
Rajarshi Sengupta
- 2:00 pm PL-03 The sonic hedgehog target YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation
Anna M. Kenney

- 2:15 pm PL-11 Pontine precursor cells of childhood are multi-potent glial progenitors
Michelle Monje
- 2:30 pm TM-02 Spatial and temporal heterogeneity provide the necessary cellular and molecular conditions for pediatric gliomagenesis
David H. Gutmann
- 2:45 pm TM-09 Nf1 loss cooperates with the p53 loss more efficient than Ink4/Arf loss in a glioma formation
Tatsuya Ozawa

3:00 pm Break

Concurrent Sessions 3:15-5:00 pm

Quality of Life/Neurocognitive

Grand Ballroom A-D

Moderated by *Jeffrey Wefel and Sherry Fox*

- 3:15 pm NC-08 Longitudinal cognitive follow-up in newly diagnosed glioblastoma patients treated with bevacizumab, temozolomide and hypofractionated stereotactic radiotherapy
Denise D. Correa
- 3:30 pm QL-07 Compromised health-related quality of life in low-grade glioma patients
M. Klein
- 3:45 pm RT-24 Neurocognitive function following cranial irradiation for pediatric brain tumors: A prospective study
Kristin J. Redmond
- 4:00 pm NC-05 Clinical utility of neurocognitive function as a prognostic factor for survival and measure of differential between-arm treatment effects on RTOG-0525
Jeffrey S. Wefel
- 4:15 pm QL-10 Prognostic importance of quality of life and fatigue in recurrent high-grade glioma patients
Katherine B. Peters
- 4:30 pm NC-11 Prediction of memory outcomes after resection of high grade glioma
Jeffrey S. Wefel
- 4:45 pm QL-22 Exploration of symptom clusters in patients with primary and metastatic brain cancer
Jennifer Cahill

Surgical Therapies

Grand Ballroom E-G

Moderated by Constantinos Hadjipanayis and John Boockvar

- 3:15 pm ST-41 The relationship between extent of resection and outcome in newly diagnosed GBM: Results from RTOG 0525
Michael A. Vogelbaum
- 3:30 pm ST-04 Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis
Philip C. De Witt Hamer
- 3:45 pm ST-17 Low-grade insular glioma resection with 1.5T intra-operative MRI: preliminary results of a prospective randomized trial
Xiaolei Chen
- 4:00 pm ST-25 Assessing performance in brain tumor debulking using a novel virtual reality simulator
Nicholas Gelinas-Phaneuf
- 4:15 pm ST-28 Stereotactic brachytherapy with 125Iodine-seeds (SBT) for treatment WHO grade II and III gliomas located in the central sulcus area
Maximilian I. Ruge
- 4:30 pm RT-05 Patient outcome and response to therapy after stereotactic radiosurgery or radiotherapy for intracranial meningiomas: Emphasis on predictive biomarker discovery
Randy L. Jensen
- 4:45 pm ST-07 An extent of resection threshold for recurrent glioblastomas
Mark E. Oppenlander

Poster Viewing Reception II 5:00-7:00 pm

Royal Ballroom

Supported by Merck

Banquet 7:15 – 10:00 pm

Grand Ballroom

Sunday, November 20, 2011

7:00-9:00 am

Breakfast in the Foyer

Sunrise Sessions 7:00-8:00 am

Atypical and Malignant Meningioma Terrace A-C

- Brachytherapy for recurrent atypical and malignant meningiomas
Michael McDermott
- Role of chemotherapy in meningiomas
Jeffrey Raizer
- Radiation Therapy for meningiomas: Review and update
Igor Barani

Molecular Pathology: Practice and Promise Harbor Room

- Stratification of adult and pediatric patients with molecular pathology
Joanna J. Phillips
- Genomics and emerging technologies in molecular pathology and trials
Keith Ligon
- Industry perspectives on molecular pathology integration in clinical trial design
Emmanuelle di Tomaso

Immunobiology Pacific Room

- Glioma vaccines targeting multiple epitopes -- Hope and Challenges in Clinical Settings
Hideo Okada
- Immunosuppressive Microenvironment:
Allen Waziri
- Adoptive T-cell Therapy
Stephen Gottschalk

Plenary Session 8:15-noon

Grand Ballroom

Medical and Neuro-Oncology - 1

Moderated by Andrew Lassman and Daniela Bota

- 8:15 am EP-11 Variation over time and inter-dependence between disease progression and death among patients with Glioblastoma(GBM) on RTOG 0525
Meihua Wang
- 8:30 am NO-64 Triple-negative low-grade gliomas: A highly aggressive tumor with dismal prognosis
Philippe Metellus
- 8:45 am NO-82 Phase II study of bevacizumab, temozolomide and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma
Antonio Omuro

- 9:00 am OT-16 NCCTG N0272: Phase II trial of imatinib mesylate; (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. A North Central Cancer Treatment Group study
Kurt A. Jaeckle
- 9:15 am OT-12 A phase I study of the smoothed (Smo) antagonist LDE225 in patients with advanced solid tumors: preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity in medulloblastoma
Jordi Rodon
- 9:30 am NO-45 IDH mutations and their role in progression of low grade gliomas
Tareq A. Juratli

9:45 am *Break*

Clinical Trials Update

Moderated by W. K. Alfred Yung

10:00 – 11:00 am Clinical trials update

Medical and Neuro-Oncology - 2

Moderated by Patrick Wen and Timothy Cloughesy

- 11:00 am NO-116 Hearing and radiographic response of NF2-related vestibular schwannoma to bevacizumab: a retrospective review of 31 patients
Scott R. Plotkin
- 11:15 am OT-09 Updated survival data of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma
Eric T. Wong
- 11:30 am EP-07 Associations of glioma risk loci by IDH mutation status
Terri Rice
- 11:45 am NO-74 IDH1 mutations in grade II astrocytomas are associated with unfavorable progression free survival and prolonged post-recurrence survival
Niklas Thon

Adjourn

JOIN SNO IN 2012 FOR THE

17th Annual Scientific Meeting

and Education Day

of the

Society for Neuro-Oncology

Washington, DC

November 15-18, 2012

